Drugs / AZD4144
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07685600 | Jul → Oct 2026 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07518459 | Feb → May 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06948006 | Apr → Jun 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06942923 | Apr → Sep 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06925854 | Apr → Jun 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06675175 | Dec 2024 → Oct 2025 | atherosclerotic cardiovascular disease, chronic kidney disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06693765 | Nov 2024 → Apr 2025 | end stage renal failure, impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06491550 | Jul 2024 → Jun 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06122714 | Nov 2023 → Dec 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07215702 | Feb 2026 → Feb 2027 expected | acute kidney injury, bacterial infectious disease with sepsis | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4144 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06675175 ↗ |
| Route | Oral | “Via Oral Administration” NCT06122714 ↗ |